Analyst Research

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Meda and Valeant terminates joint ventures


Monday, 7 Apr 2014 03:30am EDT 

Meda AB and Valeant:To terminate the companies' joint ventures in Canada, Mexico and Australia in the second quarter of 2014.In all three countries own Meda affiliates have been established.Product rights to Flupirtine, Onsolis and Sublinox are returned to Meda while Valeant will continue to run the business in Canada.As a part of the total agreement Meda will cease paying royalties on sales of Acnatac, Aldara and Zyclara to Valeant. 

Company Quote

130.2
4.8 +3.83%
11:29am EDT